Profile data is unavailable for this security.
About the company
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
- Revenue in USD (TTM)113.63m
- Net income in USD28.02m
- Incorporated2010
- Employees119.00
- LocationCytomX Therapeutics Inc151 Oyster Point Blvd., Suite 400SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 515-3185
- Fax+1 (650) 351-0353
- Websitehttps://cytomx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIOAGE Labs Inc | 5.92m | -75.79m | 817.00m | 62.00 | -- | 2.53 | -- | 138.08 | -2.04 | -2.04 | 0.1594 | 7.74 | 0.0184 | -- | -- | 95,435.48 | -23.59 | -- | -25.31 | -- | -- | -- | -1,280.90 | -- | -- | -- | 0.0147 | -- | -- | -- | -11.36 | -- | -- | -- |
| Xencor Inc | 167.36m | -138.75m | 827.65m | 250.00 | -- | 1.32 | -- | 4.95 | -1.88 | -1.88 | 2.26 | 8.76 | 0.1807 | -- | 10.46 | 669,428.00 | -15.07 | -9.89 | -16.65 | -10.95 | -- | -- | -83.42 | -48.58 | -- | -12.12 | 0.1755 | -- | -36.72 | -6.75 | -74.73 | -- | -2.93 | -- |
| Omeros Corp | 0.00 | -121.24m | 828.83m | 202.00 | -- | -- | -- | -- | -2.04 | -2.02 | 0.00 | -3.15 | 0.00 | -- | -- | 0.00 | -48.59 | -50.90 | -66.86 | -63.20 | -- | -- | -- | -- | -- | -- | 2.72 | -- | -- | -- | -4.41 | -- | -13.15 | -- |
| SS Innovations International Inc | 33.57m | -17.11m | 834.51m | 378.00 | -- | 21.04 | -- | 24.86 | -0.0959 | -0.0959 | 0.1822 | 0.2048 | 0.6253 | 1.19 | 5.09 | 88,820.32 | -31.86 | -77.47 | -50.87 | -137.45 | 48.25 | 23.69 | -50.96 | -169.09 | 1.34 | -- | 0.2025 | -- | 251.46 | -- | 8.27 | -- | 67.53 | -- |
| ARS Pharmaceuticals Inc | 142.77m | -80.04m | 874.81m | 162.00 | -- | 5.92 | -- | 6.13 | -0.9012 | -0.9012 | 1.38 | 1.49 | 0.4836 | 3.56 | 7.67 | 921,109.70 | -27.11 | -14.27 | -30.61 | -14.82 | 89.40 | -- | -56.06 | -224.85 | 6.51 | -- | 0.3946 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| Aktis Oncology Inc | 5.56m | -60.65m | 899.53m | -- | -- | -- | -- | 161.79 | -1.20 | -1.20 | 0.1098 | 3.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,090.81 | -- | -- | -- | 0.00 | -- | -- | -- | -53.56 | -- | -- | -- |
| BridgeBio Oncology Therapeutics Inc | 0.00 | 4.72m | 899.87m | -- | 56.36 | 1.40 | -- | -- | 0.1996 | 0.1996 | 0.00 | 8.05 | 0.00 | -- | -- | -- | 2.44 | -- | 2.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18,328.62 | -- | -- | -- |
| CytomX Therapeutics Inc | 113.63m | 28.02m | 901.40m | 119.00 | 13.21 | 8.18 | 30.77 | 7.93 | 0.4027 | 0.4027 | 0.9733 | 0.6506 | 0.7646 | -- | 45.63 | 954,882.40 | 18.85 | -15.58 | 40.91 | -26.48 | -- | -- | 24.66 | -50.39 | -- | -- | 0.00 | -- | 36.45 | 19.16 | 5,700.88 | -- | -38.41 | -- |
| Fortrea Holdings Inc | 2.76bn | -1.03bn | 904.60m | 14.50k | -- | 1.55 | -- | 0.3278 | -11.38 | -11.24 | 30.33 | 6.30 | 0.8617 | -- | 4.08 | 178,058.10 | -32.08 | -- | -43.77 | -- | 18.61 | -- | -37.23 | -- | -- | -0.5534 | 0.6598 | -- | -5.14 | -- | -756.47 | -- | -- | -- |
| GH Research PLC | 0.00 | -42.92m | 911.83m | 50.00 | -- | 3.13 | -- | -- | -0.7313 | -0.7313 | 0.00 | 4.70 | 0.00 | -- | -- | 0.00 | -17.11 | -12.39 | -17.83 | -12.66 | -- | -- | -- | -- | -- | -- | 0.002 | -- | -- | -- | -9.48 | -- | -- | -- |
| Arrivent Biopharma Inc | 0.00 | -151.40m | 927.18m | 52.00 | -- | 3.01 | -- | -- | -4.24 | -4.24 | 0.00 | 7.47 | 0.00 | -- | -- | 0.00 | -48.90 | -- | -51.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.09 | -- | -- | -- |
| AbCellera Biologics Inc | 35.32m | -171.68m | 927.94m | 596.00 | -- | 0.9615 | -- | 26.27 | -0.5765 | -0.5765 | 0.1187 | 3.22 | 0.0257 | -- | 0.97 | 59,268.46 | -12.49 | 2.01 | -13.20 | 2.20 | -- | -- | -486.01 | 10.48 | -- | -- | 0.00 | 0.00 | -24.17 | 19.95 | -11.24 | -- | 81.35 | -- |
| Palvella Therapeutics Inc | 0.00 | -35.07m | 965.15m | 14.00 | -- | 23.37 | -- | -- | -3.83 | -3.83 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -80.19 | -31.18 | -96.21 | -43.15 | -- | -- | -- | -122.22 | -- | -3.05 | 0.2929 | -- | -100.00 | -- | 28.97 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -135.27m | 972.92m | 106.00 | -- | 2.39 | -- | -- | -1.73 | -1.73 | 0.00 | 4.18 | 0.00 | -- | -- | 0.00 | -36.90 | -36.70 | -39.10 | -38.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.96 | -- | 9.12 | -- |
Data as of Feb 13 2026. Currency figures normalised to CytomX Therapeutics Inc's reporting currency: US Dollar USD
42.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 13.07m | 7.93% |
| Tang Capital Management LLCas of 30 Sep 2025 | 11.07m | 6.71% |
| Perceptive Advisors LLCas of 30 Sep 2025 | 9.68m | 5.87% |
| Commodore Capital LPas of 30 Sep 2025 | 7.69m | 4.66% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.61m | 4.61% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 5.14m | 3.12% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 4.25m | 2.58% |
| Point72 Asset Management LPas of 30 Sep 2025 | 4.07m | 2.47% |
| Adar1 Capital Management LLCas of 30 Sep 2025 | 4.05m | 2.45% |
| Balyasny Asset Management LPas of 30 Sep 2025 | 3.91m | 2.37% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
